AUROLAB.BO logo
BSE · AUROLAB.BOMedical - PharmaceuticalsUpdated Nov 11, 2026

Auro Laboratories Limited P/E ratio

Current valuation, historical context, and peer comparisons.

Current P/E ratio

30.57×

24.0% abovethe 10-year annual average

Share price229.9
÷
Earnings per share7.52

Price and EPS in quote currency. Calculation details

Investors are paying 30.57 for every 1 of reported earnings per share.

P/E over time

2017 – 2026
Annual P/ESelected-period average 24.65×
3-year average47.52×3 positive annual observations
5-year average35.70×5 positive annual observations
10-year average24.65×10 positive annual observations
Peer median · TTM22.67×6 peers with positive P/E

Historical P/E ratios

Annual period-end data · 19 observations

AUROLAB.BO annual P/E history, newest first
Period endP/EChange
Mar 31, 202646.65×-43.1%
Mar 31, 202582.00×+489.8%
Mar 31, 202413.90×-0.2%
Mar 31, 202313.94×-36.6%
Mar 31, 202222.00×+212.4%
Mar 31, 20217.04×+45.7%
Mar 31, 20204.83×-43.8%
Mar 31, 20198.60×-45.9%
View all 19 annual observations +
AUROLAB.BO annual P/E history, newest first
Period endP/EChange
Mar 31, 201815.90×-49.8%
Mar 31, 201731.68×+122.8%
Mar 31, 201614.22×+154.1%
Mar 31, 20155.60×-12.7%
Mar 31, 20146.41×-4.0%
Mar 31, 20136.67×-49.6%
Mar 31, 201213.24×-33.4%
Mar 31, 201119.88×-45.6%
Mar 31, 201036.54×+46.2%
Mar 31, 200925.00×-63.0%
Mar 31, 200867.57×N/M

Change is relative to the preceding observation. N/M values are excluded from averages.

How AUROLAB.BO compares

Company P/E vs. peer trailing-12-month ratios

P/E comparison with AUROLAB.BO and provider-selected peers
CompanyP/E ratio
AUROLAB.BO logo
AUROLAB.BO This stockAuro Laboratories Limited
30.57×
AUROPHARMA.NS logo
AUROPHARMA.NSAurobindo Pharma Limited
26.37×
VRL.BO logo
VRL.BOVasundhara Rasayans Limited
7.70×
AAREYDRUGS.NS logo
AAREYDRUGS.NSAarey Drugs & Pharmaceuticals Limited
73.73×
PANCHSHEEL.BO logo
PANCHSHEEL.BOPanchsheel Organics Limited
13.53×
SYSCHEM.BO logo
SYSCHEM.BOSyschem (India) Limited
21.96×
GODAVARI.BO logo
GODAVARI.BOGodavari Drugs Limited
23.38×
LASA.NS logo
LASA.NSLasa Supergenerics Limited
N/M
MANGALAM.NS logo
MANGALAM.NSMangalam Drugs & Organics Limited
N/M

Peers are selected by the data provider. Business models and earnings definitions can differ.

Put the numbers in context

What does AUROLAB.BO’s P/E tell you?

01

Start with its own history

At 30.57×, AUROLAB.BO is 24.0% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

02

Compare like with like

The median of the 6 positive peer ratios above is 22.67×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.

03

Check what drives earnings

One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.

Keep your research connected

Take AUROLAB.BO into your spreadsheet

Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.

Explore Wisesheets
Quarterly P/E · latest quarter
=WISE("AUROLAB.BO", "PE Ratio", "LQ")
LQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data

Sources & calculation methodology

Current P/E

Share price 229.9 ÷ EPS 7.52 = 30.57×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 11, 2026; this is not a real-time trading quote.

History & averages

Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.

Data definitions and limitations

The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.

AUROLAB.BO P/E ratio: common questions

The essentials behind the numbers.

Auro Laboratories Limited's current P/E is 30.57× based on the quote data last updated Nov 11, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.